延长释放的阿曼塔丁用于帕金森病中OFF相关的 dystonia
Alberto J Espay1, Jill L Ostrem2, Andrea E Formella3
1James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, Cincinnati, OH, 45267, USA; Department of Neurology, University of Cincinnati, Cincinnati, OH, 45267, USA.
Parkinsonism & related disorders
|March 10, 2024
概括
延长释放的阿曼塔丁在帕金森病 (PD) 患者中有效降低了与OFF相关的疼痛性 dystonia. 这些改进持续了两年,并且独立于OFF时间的变化.
科学领域:
- 神经学 神经学
- 运动障碍 运动障碍
- 帕金森病 帕金森病
背景情况:
- 腹痛是帕金森病 (PD) 的一个显著而痛苦的并发症,经常发生在OFF期间.
- 目前PD中 dystonia 的治疗选择有限,这凸显了对有效疗法的需要.
研究的目的:
- 评估延长释放阿曼塔丁在治疗帕金森病患者的OFF相关 dystonia 的疗效.
- 为了评估治疗效果在两年时间内的持久性.
主要方法:
- 从两个关键试验及其涉及延长释放阿曼塔丁的开放式扩展组合数据的后期分析.
- 用统一运动障碍评分表 (UDysRS) 第2部分和 MDS-UPDRS 4.6. 项来测量 dystonia.
主要成果:
- 超过60%的参与者在基线报告了OFF相关的 dystonia.
- 与安慰剂相比,12周的延长释放阿曼塔丁治疗显著改善了 dystonia 症状.
- dystonia 的改善持续了长达两年,并且与 OFF 时间的变化无关.
结论:
- 延长释放的阿曼塔丁在帕金森病患者中持续减少了OFF相关的 dystonia.
- 对 dystonia 的治疗益处似乎独立于对运动波动 (OFF 时间) 的影响.
- 建议进行随机对照试验来验证这些发现.
相关概念视频
Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268
Parkinson's Disease: Overview
544
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
544
Alzheimer's Disease: Treatment
188
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
188
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
680
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
680
Direct-Acting Cholinergic Agonists: Therapeutic Uses
740
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
740
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
673
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
673


